title: Is Hyperuricemia Overlooked when Treating Pediatric Tuberculosis Patients with Pyrazinamide?
abstract: The treatment of tuberculosis (TB) requires long-term multiple drug use. Hyperuricemia is frequently reported in adults, but there are few data for the pediatric population. This study aimed to review drug-related side effects in pediatric patients that received treatment for TB. Patients with active TB undergoing treatment were followed for drug-related side effects. During the 7 year period, 23 patients with a mean age of 7.9 ± 4.66 years were treated. Drug-related side effects were observed in 14 patients. Hyperuricemia occurred in 12 of the 14 patients, vs. hepatotoxicity in 2. In all, eight of the patients with hyperuricemia had ≥2 episodes during pyrazinamide (PZA) therapy. Based on these findings, we devised an algorithm that could be used for the management of hyperuricemia in patients receiving PZA because of TB, and recommend that hyperuricemia be closely monitored during PZA therapy.
authors.affiliation: Pediatric Pulmonology Department, Gazi University Hospital, 06500 Beşevler, Ankara, Turkey tsismanlar@yahoo.com.
authors.forename: Tuğba
authors.initials: T
authors.lastname: Şişmanlar
authors.affiliation: Pediatric Pulmonology Department, Gazi University Hospital, 06500 Beşevler, Ankara, Turkey.
authors.forename: Ayşe T
authors.initials: AT
authors.lastname: Aslan
authors.affiliation: Medical Education Department, Gazi University Hospital, 06500 Beşevler, Ankara, Turkey.
authors.forename: Irem
authors.initials: I
authors.lastname: Budakoğlu
mesh_terms: D000293:Adolescent; D000493:Allopurinol / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D033461:Hyperuricemia / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy; D008297:Male; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D011718:Pyrazinamide / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome; D014376:Tuberculosis / Q000188:drug therapy*; D014527:Uric Acid / Q000097:blood*
chemical_list: D000995:Antitubercular Agents; D014527:Uric Acid; D011718:Pyrazinamide; D000493:Allopurinol